These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14934125)

  • 41. The lupus erythematosus cell and its significance.
    WILKINSON M; SACKER LS
    Br Med J; 1957 Sep; 2(5046):661-5. PubMed ID: 13460347
    [No Abstract]   [Full Text] [Related]  

  • 42. [The problem of the specificity of the lupus erythematosus cell phenomenon].
    STUHLERT H
    Z Haut Geschlechtskr; 1955 Jul; 19(1):3-6. PubMed ID: 13248031
    [No Abstract]   [Full Text] [Related]  

  • 43. The L.E. (lupus erythematosus) cell reaction.
    OGRYZLO MA
    Can Med Assoc J; 1956 Dec; 75(12):980-93. PubMed ID: 13374645
    [No Abstract]   [Full Text] [Related]  

  • 44. An update on pathogenesis of systemic lupus erythematosus.
    Ahmadpoor P; Dalili N; Rostami M
    Iran J Kidney Dis; 2014 May; 8(3):171-84. PubMed ID: 24878938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The phenomenon of autoerythrophagocytosis in vitro; comparison with formative mechanism and attempt to interpret the so-called lupus erythematosus cells].
    CAPPELLI E
    Minerva Dermatol; 1952 May; 27(5):108-14. PubMed ID: 12982584
    [No Abstract]   [Full Text] [Related]  

  • 46. Relapsing polychondritis in a patient with lupus erythematosus: another manifestation of neutrophilic lupus?
    Lenormand C; Scrivener Y
    Dermatology; 2008; 217(3):211. PubMed ID: 18594144
    [No Abstract]   [Full Text] [Related]  

  • 47. [ON THE ANTINUCLEAR FACTOR IN COLLAGEN DISEASES, WITH SPECIAL REFERENCE TO ACUTE LUPUS ERYTHEMATOSUS].
    MINAMI K; KODA H; TOGEGAWA S
    Fukuoka Igaku Zasshi; 1964 Mar; 55():167-73. PubMed ID: 14165106
    [No Abstract]   [Full Text] [Related]  

  • 48. Path-finder: lupus erythematosus and the L.E. cell.
    Blum LL
    J Indiana State Med Assoc; 1971 Jan; 64(1):34-5. PubMed ID: 4099845
    [No Abstract]   [Full Text] [Related]  

  • 49. SYSTEMIC LUPUS ERYTHEMATOSUS: ANALYSIS OF DATA OF 7 CASES.
    BANERJEE AK; BASU N
    Bull Calcutta Sch Trop Med; 1963 Oct; 11():139. PubMed ID: 14120847
    [No Abstract]   [Full Text] [Related]  

  • 50. Diagnosis and management of systemic lupus erythematosus.
    Kaplan D; Sadovsky R
    Am Fam Physician; 1978 Jan; 17(1):133-8. PubMed ID: 74945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chronic disseminated lupus erythematosus in the light of our observations].
    Filipiuk J
    Przegl Dermatol; 1969; 56(1):39-44. PubMed ID: 4182964
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immunological staging in lupus erythematosus. Basic data and practical significance].
    Bauer R; Schütz R; Stadler R
    Z Hautkr; 1982 Aug; 57(15):1091-6, 1100. PubMed ID: 6181624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.
    García-Carrasco M; Mendoza-Pinto C; Macías-Díaz S; Etchegaray-Morales I; Méndez-Martínez S; Soto-Santillán P; Pérez-Romano B; Jiménez-Herrera EA; Guzmán-Ruiz O; Ruiz-Argüelles A
    Clin Rheumatol; 2017 Oct; 36(10):2267-2272. PubMed ID: 28616661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The "L.E. cell" a phenomenon of diagnostic value in acute disseminated lupus erythematosus.
    STEVENS JE; WINE JF; PEPPLE A; RADER ME
    Va Med Mon (1918); 1951 Nov; 78(11):590-7. PubMed ID: 14877057
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
    Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
    Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The L.E. (lupus erythematosus) cell; clinical and chemical studies.
    LEE SL; MICHAEL SR; VURAL IL
    Am J Med; 1951 Apr; 10(4):446-51. PubMed ID: 14819050
    [No Abstract]   [Full Text] [Related]  

  • 57. [DEMONSTRATION OF THE LE FACTOR BY THE IMMUNOFLUORESCENT METHOD].
    KRAMAR J; STREJCEK J; REJHOLEC V
    Cas Lek Cesk; 1964 Mar; 103():255-8. PubMed ID: 14138932
    [No Abstract]   [Full Text] [Related]  

  • 58. [Rebuck and Crowley test in lupus erythematosus].
    Kisselewa ML; Trofimowa LJ
    Hautarzt; 1966 May; 17(5):219-22. PubMed ID: 4168869
    [No Abstract]   [Full Text] [Related]  

  • 59. DISSEMINATED LUPUS ERYTHEMATOSUS.
    CHELVARAJAH T; RATNAIKE VT
    Ceylon Med J; 1962; 7():231-5. PubMed ID: 14073596
    [No Abstract]   [Full Text] [Related]  

  • 60. [OUR PRESENT EXPERIENCE IN DIAGNOSIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS].
    VANCAUWENBERGE H; FRANCHIMONT P; LAMBERT PH; LAPIERE CM; LEFEBVRE P; LISIN N; SALMON J
    Sem Hop; 1964 Nov; 40():2769-75. PubMed ID: 14245789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.